A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group, Uro-Oncology Clinic, Centre Hospitalier de l'Universite, de Montreal, Hopital Notre-Dame, Montreal, Quebec, Canada - J Natl Cancer Inst 2002;94:1458-1468

Author： Trump D.L.  

Publisher： Elsevier

ISSN： 1078-1439

Source： Urologic Oncology: Seminars and Original Investigations, Vol.21, Iss.5, 2003-09, pp. : 408-408

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

By Zaghloul Mohamed   Boutrus Rimoun   El-Hossieny Hisham   Kader Yasser   El-Attar Inas   Nazmy Mohamed  

International Journal of Clinical Oncology, Vol. 15, Iss. 4, 2010-08 ,pp. : 382-389

Springer Publishing Company

Access to resources Recommend Favorite

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD - J Clin Oncol 2003;21:679-689

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 410-411

Elsevier

Access to resources Recommend Favorite

Jaw complications in breast and prostate cancer patients treated with zoledronic acid

By Ortega C.   Faggiuolo R.   Vormola R.   Montemurro F.   Nanni D.   Goia F.   Aglietta M.  

Acta Oncologica, Vol. 45, Iss. 2, 2006-03 ,pp. : 216-217

Informa Healthcare

Access to resources Recommend Favorite

Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial

By Uemura Hiroji  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 472-477

Springer Publishing Company

Access to resources Recommend Favorite

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy - D'Aimco AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M-H, Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA. J Natl Cancer Inst 2003;95:1376-1383

By Chatta G.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 487-488

Elsevier

Access to resources Recommend Favorite